- ASCO® 2024
- Yale Cancer Answers
- ASH CME Series
- Smilow Shares with Primary Care
- Grand Rounds
- Head and Neck
- Gynecologic
- Benign Hematology
- Breast
- GI
- Lung
- GU
- Hematologic Oncology
- Brain
- Cancer Screening
- DEI (Diversity, Equity and Inclusion)
- 2021 ASH Highlights
- General Events
- Events
Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
0:00
Stream Type LIVE
Remaining Time -0:00
1x
- 0.5x
- 0.75x
- 1x, selected
- 1.25x
- 1.5x
- 1.75x
- 2x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
10 seconds
Playback speed
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
IO Mechanisms of Cancer Resistance: What Is the Efficacy of CPIs in Melanoma? How to Overcome IO Resistance With Targeting dsRNA? Can ADAR1 Deletion Overcome Resistance to CPIs?
By
Yale Cancer Center
FEATURING
Jeffrey Ishizuka
By
Yale Cancer Center
FEATURING
Jeffrey Ishizuka
9 views
January 28, 2021
Comments 0
Login to view comments.
Click here to Login